SLS 8-K
SELLAS Life Sciences Group, Inc. (SLS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| (Address of Principal Executive Offices) (Zip Code) |
||||
| Registrant’s
telephone number, including area code: ( | ||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) |
Name of each exchange
on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
As of June 30, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $138.3 million. This amount is unaudited and preliminary and is subject to the completion of financial closing procedures, including management’s reviews. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the six months ended June 30, 2026.
| Item 8.01 | Other Events |
As previously disclosed, the Company commenced a binding arbitration against 3D Medicines, Inc. (“3D Medicines”), administered by the Hong Kong International Arbitration Centre (“HKIAC”). On July 24, 2026, the sole arbitrator in the arbitration proceeding rendered a decision dismissing the Company’s claims. As permitted by HKIAC rules, the arbitrator administratively allocated a portion of 3D Medicines’ legal fees and costs in the amount of approximately $1.0 million to be paid by the Company.
3D Medicines announced that it will continue to progress the development and commercialization of galinpepimut-S (“GPS”) in the Greater China territory in accordance with the terms of the exclusive license agreement, pursuant to which $191.5 million in potential future milestone payments remain as of March 31, 2026, including the $13.0 million milestone payments that were in dispute in the arbitration.
2
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit Number | Description | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SELLAS Life Sciences Group, Inc. | ||||
| Date: | July 27, 2026 | By: | /s/ John T. Burns | |
| Name: | John T. Burns | |||
| Title: | Senior Vice President, Chief Financial Officer | |||
4